PT - JOURNAL ARTICLE AU - Mitjà, Oriol AU - Ubals, Maria AU - Corbacho-Monné, Marc AU - Alemany, Andrea AU - Suñer, Clara AU - Tebe, Cristian AU - Tobias, Aurelio AU - Peñafiel, Judith AU - Ballana, Ester AU - Pérez, Carla A. AU - Admella, Pol AU - Riera-Martí, Nuria AU - Laporte, Pep AU - Mitja, Jordi AU - Clua, Mireia AU - Bertran, Laia AU - Sarquella, Maria AU - Gavilán, Sergi AU - Ara, Jordi AU - Argimon, Josep M AU - Cuatrecasas, Gabriel AU - Cañadas, Paz AU - Elizalde-Torrent, Aleix AU - Fabregat, Robert AU - Farré, Magí AU - Forcada, Anna AU - Flores-Mateo, Gemma AU - López, Cristina AU - Muntada, Esteve AU - Nadal, Núria AU - Narejos, Silvia AU - Gil-Ortega, Aroa N AU - Prat, Nuria AU - Puig, Jordi AU - Quiñones, Carles AU - Ramírez-Viaplana, Ferran AU - Urueña, Juliana Reyes- AU - Riveira-Muñoz, Eva AU - Ruiz, Lidia AU - Sanz, Sergi AU - Sentis, Alexis AU - Sierra, Alba AU - Velasco, César AU - Vivanco-Hidalgo, Rosa Maria AU - Zamora, Juani AU - on behalf of the BCN PEP-COV RESEARCH GROUP AU - Casabona, Jordi AU - Vall-Mayans, Martí AU - G-Beiras, Camila AU - Clotet, Bonaventura TI - A Cluster-Randomized Trial of Hydroxychloroquine as Prevention of Covid-19 Transmission and Disease AID - 10.1101/2020.07.20.20157651 DP - 2020 Jan 01 TA - medRxiv PG - 2020.07.20.20157651 4099 - http://medrxiv.org/content/early/2020/07/26/2020.07.20.20157651.short 4100 - http://medrxiv.org/content/early/2020/07/26/2020.07.20.20157651.full AB - Background Current strategies for preventing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections are limited to non-pharmacological interventions. Hydroxychloroquine (HCQ) has been proposed as a postexposure therapy to prevent Coronavirus disease 2019 (Covid-19) but definitive evidence is lacking.Methods We conducted an open-label, cluster-randomized trial including asymptomatic contacts exposed to a PCR-positive Covid-19 case in Catalonia, Spain. Clusters were randomized to receive no specific therapy (control arm) or HCQ 800mg once, followed by 400mg daily for 6 days (intervention arm). The primary outcome was PCR-confirmed symptomatic Covid-19 within 14 days. The secondary outcome was SARS-CoV-2 infection, either symptomatically compatible or a PCR-positive result regardless of symptoms. Adverse events (AEs) were assessed up to 28 days.Results The analysis included 2,314 healthy contacts of 672 Covid-19 index cases identified between Mar 17 and Apr 28, 2020. A total of 1,198 were randomly allocated to usual care and 1,116 to HCQ therapy. There was no significant difference in the primary outcome of PCR-confirmed, symptomatic Covid-19 disease (6.2% usual care vs. 5.7% HCQ; risk ratio 0.89 [95% confidence interval 0.54-1.46]), nor evidence of beneficial effects on prevention of SARS-CoV-2 transmission (17.8% usual care vs. 18.7% HCQ). The incidence of AEs was higher in the intervention arm than in the control arm (5.9% usual care vs 51.6% HCQ), but no treatment-related serious AEs were reported.Conclusions Postexposure therapy with HCQ did not prevent SARS-CoV-2 disease and infection in healthy individuals exposed to a PCR-positive case. Our findings do not support HCQ as postexposure prophylaxis for Covid-19.ClinicalTrials.gov registration number NCT04304053Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04304053Funding StatementCrowdfunding campaign YoMeCorono (https://www.yomecorono.com/), Laboratorios Rubio, Laboratorios Gebro Pharma, Zurich Seguros, SYNLAB Barcelona, and Generalitat de Catalunya. Laboratorios Rubio also contributed to the study with the required doses of hydroxychloroquine (Dolquine).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol and subsequent amendments were approved by the institutional review board of Hospital Germans Trias Pujol, and the Spanish Agency of Medicines and Medical Devices.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe study protocol and raw data will be available for a year upon request to the corresponding author